Physician profile
Jack Mannheimer
NPI 1619076353
$9,352.84
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $1,924 · 2021: $2,338 · 2022: $1,956 · 2023: $1,819 · 2024: $29.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,334.24 | 2021-2024 | |
| Allergan, INC. | $946.14 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $848.86 | 2019-2023 | Uzedy, Austedo, Austedo Xr |
| Lundbeck LLC | $678.29 | 2019-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $614.33 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $607.96 | 2019-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $529.87 | 2019-2023 | Trintellix |
| Alkermes, INC. | $467.90 | 2019-2023 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $413.90 | 2019-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $399.52 | 2020-2023 | |
| Almatica Pharma LLC | $359.99 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Vanda Pharmaceuticals INC. | $295.83 | 2019-2022 | |
| Eisai INC. | $242.21 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $195.73 | 2019-2021 | |
| Indivior INC. | $110.84 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $79.93 | 2019-2021 | |
| Bausch Health US, LLC | $53.80 | 2019-2022 | |
| Corium, LLC | $53.24 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $45.93 | 2022-2023 | Qelbree |
| Shire North American Group INC | $19.38 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.84 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.21 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $17.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Mannheimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.